Effects of Statin Therapy on Exercise Levels in Participants in the National Runners' and Walkers' Health Study

Mayo Clinic Proceedings

Volumn 90, Issue 10, 2015, Pages 1338-1347

  Williams, Paul T ^a   Thompson, Paul D ^b  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Abbreviations and Acronyms difference between baseline and follow up; BMI body mass index; CK creatine kinase; LDL C low density lipoprotein cholesterol; MET h d metabolic equivalents hours per day; VO2max maximum oxygen consumption

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; CERIVASTATIN; CHOLESTIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXERCISE INTENSITY; FEMALE; FITNESS; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MARATHON RUNNER; MIDDLE AGED; RUNNING; WALKING; WEIGHT GAIN; BLOOD; DOSE RESPONSE; DRUG EFFECTS; EXERCISE TOLERANCE; HEALTH SURVEY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; UNITED STATES;

ADULT; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MUSCLE, SKELETAL; OUTCOME ASSESSMENT (HEALTH CARE); RUNNING; UNITED STATES; WALKING;

EID: 84955346134     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.06.019     Document Type: Article

References (43)

1. Thompson PD, Clarkson P, Karas RH. Statin-Associated myopathy. JAMA. 2003;289(13):1681-1690.
2. Auer J, Sinzinger H, Franklin B, Berent R. Muscle-And skeletalrelated side-effects of statins: Tip of the iceberg [published online September 17, 2014]? Eur J Prev Cardiol. 2014.
3. Murlasits Z, Radák Z. The effects of statin medications on aerobic exercise capacity and training adaptations. Sports Med. 2014;44(11):1519-1530.
4. Sirvent P, Fabre O, Bordenave S, et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol. 2012;259(2):263-268.
5. Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther. 2007;81(5): 650-653.
6. Stringer HA, Sohi GK, Maguire JA, Cote HC. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J Neurol Sci. 2013;325(1-2):142-147.
7. Lee DS, Markwardt S, Goeres L, et al. Statins and physical activity in older men: The osteoporotic fractures in men study. JAMA Intern Med. 2014;174(8):1263-1270.
8. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6-15.
9. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788-2797.
10. Panza GA, Taylor BA, Roman W, Thompson PD. Changes in muscle strength in patients with statin myalgia. Am J Cardiol. 2014;114(8):1215-1216.
11. Parker BA, Capizzi JA, Grimaldi AS, et al. The effect of statins on skeletal muscle function. Circulation. 2013;127(1):96-103.
12. Ballard KD, Parker BA, Capizzi JA, et al. Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis. 2013;230: 121-124.
13. Williams PT. Vigorous exercise, fitness and incident hypertension, high cholesterol, and diabetes. Med Sci Sports Exerc. 2008;40(6):998-1006.
14. Williams PT, Thompson PD. Walking versus running for hypertension, cholesterol, and diabetes mellitus risk reduction. Arterioscler Thromb Vasc Biol. 2013;33(5):1085-1091.
15. Williams PT. Incident hypercholesterolemia in relation to changes in vigorous physical activity. Med Sci Sports Exerc. 2009;41(1):74-80.
16. Williams PT, Franklin B. Vigorous exercise and diabetic, hypertensive, and hypercholesterolemia medication use. Med Sci Sports Exerc. 2007;39(11):1933-1941.
17. Williams PT. Relationship of distance run per week to coronary heart disease risk factors in 8283 male runners: The National Runners Health Study. Arch Intern Med. 1997; 157(2):191-198.
18. Williams PT. Non-exchangeability of running vs. other exercise in their association with adiposity, and its implications for public health recommendations. PLoS One. 2012;7(7): e36360.
19. Williams PT. Advantage of distance-versus time-based estimates of walking in predicting adiposity. Med Sci Sports Exerc. 2012;44(9):1728-1737.
20. Balke B, Ware RW. An experimental study of physical fitness of Air Force personnel. U S Armed Forces Med J. 1959;10(6):875-888.
21. Hellerstein HK. Limitations of marathon running in the rehabilitation of coronary patients: Anatomic and physiologic determinants. Ann N Y Acad Sci. 1977;301:484-494.
22. Cooper KH. A means of assessing maximal oxygen intake: correlation between field and treadmill testing. JAMA. 1968;203(3): 201-204.
23. Terpak K, Guthrie S, Erickson S. Statin use and self-reported swimming performance in US masters swimmers. J Sports Sci. 2015;33(3):1-7.
24. Traustadottir T, Stock AA, Harman SM. High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. Age (Dordr). 2008;30(4):283-291.
25. Golomb BA. Statins and activity, proceed with caution. JAMA Intern Med. 2014;174(8):1270-1272.
26. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25, pt B):2960-2984.
27. Williams PT, Krauss RM, Wood PD, Lindgren FT, Giotas C, Vranizan KM. Lipoprotein subfractions of runners and sedentary men. Metabolism. 1986;35(1):45-52.
28. Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62(8):709-714.
29. Muraki A, Miyashita K, Mitsuishi M, Tamaki M, Tanaka K, Itoh H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-Treated mice and increases exercise endurance. J Appl Physiol (1985). 2012;113(3):479-486.
30. Bouitbir J, Charles AL, Rasseneur L, et al. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol. 2011; 111(5):1477-1483.
31. Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. Metabolism. 2009;58(7):1030-1038.
32. Rengo JL, Savage PD, Toth MJ, Ades PA. Statin therapy does not attenuate exercise training response in cardiac rehabilitation. J Am Coll Cardiol. 2014;63(19):2050-2051.
33. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol. 2005;19(1):117-125.
34. Päivä H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial. Clin Pharmacol Ther. 2005;78(1):60-68.
35. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: The PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403-414.
36. Bouitbir J, Daussin F, Charles AL, et al. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins. Muscle Nerve. 2012;46(3):367-373.
37. Schaefer WH, Lawrence JW, Loughlin AF, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol. 2004;194(1):10-23.
38. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol. 2005;33(2):246-257.
39. Meador BM, Huey KA. Statin-Associated changes in skeletal muscle function and stress response after novel or accustomed exercise. Muscle Nerve. 2011;44(6):882-889.
40. Kumar A, Vashist A, Kumar P, Kalonia H, Mishra J. Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice. Pharmacol Rep. 2012; 64(6):1326-1336.
41. Sinzinger H, OGrady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004; 57(4):525-528.
42. Margetts B, Vorster H, Venter C. Evidence-based nutrition: The impact of information and selection bias on the interpretation of individual studies. South Afr J Clin Nutr. 2003;16(3):78-87.
43. Loftus E, Smith K, Klinger M, Fiedler J. Memory and mismemory for health events. In: Tanur JM, ed. Questions About Questions: Inquiries Into the Cognitive Bases of Surveys. New York, NY: Russell Sage Foundation; 1991:102-137.